广东广信君达律师事务所 关于 珠海润都制药股份有限公司 2025 年第一次临时股东会的 法律意见书 二〇二五年四月 地址：广东省广州市天河区珠江新城珠江东路 6 号广州周大福金融中心 29 层、10 层、11 层（01-04 单元、10-11 单元） 邮编（P.C）：510623 电话（Tel）：020-37181333 传真（Fax）：020-37181388 网址（Website）：www.etrlawfirm.com 法律意见书 广东广信君达律师事务所 关于珠海润都制药股份有限公司 2025 年第一次临时股东会的法律意见书 （（2025）粤广信君达律委字第 1378-1 号 致：珠海润都制药股份有限公司 广东广信君达律师事务所（（以下简称"本所"）接受珠海润都制药股份有限公 司（（以下简称"公司"）的委托，指派律师（（以下简称"本所律师"）出席公司 2025 年第一次临时股东会（（以下简称"本次股东会"），并获授权依据（ 中华人民共和 国公司法》（以下简称（ 公司法》）、（ 中华人民共和国证券法》 上市公司股 东会规则》和（ 珠海润都制药股份有限公司章程》（以下简称（ 公司章程》）的 有关规定出具本法律 ...

珠海润都制药股份有限公司 章 程 第一章 总 则 | 第一章 | 总 | 则 2 | | --- | --- | --- | | 第二章 | | 经营宗旨和范围 2 | | 第三章 | 股 | 份 3 | | 第一节 | | 股份发行 3 | | 第二节 | | 股份增减和回购 4 | | 第三节 | | 股份转让 5 | | 第四章 | | 股东和股东大会 6 | | 第一节 | | 股东 6 | | 第二节 | | 股东大会的一般规定 8 | | 第三节 | | 股东大会的召集 11 | | 第四节 | | 股东大会的提案与通知 12 | | 第五节 | | 股东大会的召开 13 | | 第六节 | | 股东大会的表决和决议 16 | | 第五章 | | 董事会 21 | | 第一节 | | 董事 21 | | 第二节 | | 董事会 24 | | 第三节 | | 董事会专门委员会 29 | | 第六章 | | 总经理及其他高级管理人员 31 | | 第七章 | | 监事会 33 | | 第一节 | | 监事 33 | | 第二节 | | 监事会 33 | | 第八章 | | 财务会计制度、利润分配和审计 ...

Investment Rating - The report maintains a "Hold" rating for the healthcare sector [8] Core Viewpoints - The pharmaceutical sector slightly underperformed the CSI 300 index, with a decline of 5.61% from April 7 to April 11, 2025, ranking 22nd among 31 sectors [3][13] - Year-to-date, the pharmaceutical index has decreased by 1.10%, outperforming the CSI 300 index by 3.59 percentage points, ranking 13th among 31 sectors [15] - As of April 11, 2025, the valuation of the pharmaceutical sector stands at 25.91 times (TTM overall method, excluding negative values), with a premium of 141.73% compared to the CSI 300 index [18] Summary by Sections 1. Market Performance Review - The pharmaceutical sector's performance from April 7 to April 11, 2025, shows a decline of 5.61%, underperforming the CSI 300 index by 2.74 percentage points [3][13] - The valuation level of the pharmaceutical sector is reported at 25.91 times, with a significant premium over the CSI 300 index [18] - Top-performing stocks include Yirui Technology (+20.54%), Yipinhong (+17.03%), and Yong'an Pharmaceutical (+13.93%) [19][20] 2. Important Policies and Events - On April 7, 2025, the Ministry of Commerce and the National Health Commission, along with 12 other departments, issued the "Special Action Plan for Promoting Healthy Consumption" to enhance the quality of health goods and services [5][22] 3. Important Company Announcements - Haizike reported a revenue of 3.721 billion yuan for 2024, a year-on-year increase of 10.92%, with a net profit of 395 million yuan, up 34.00% [23] - Kexing Pharmaceutical announced a revenue of 1.407 billion yuan for 2024, with a net profit of 31 million yuan, marking a return to profitability [23] 4. Industry Perspectives - The report discusses the impact of the ongoing trade war, noting that while pharmaceuticals were initially included in tariff discussions, they were later excluded from the "reciprocal tariffs" announced by the U.S. government [6][25] - The report highlights that increased tariffs on imports from the U.S. could benefit domestic substitutes in the blood products, high-end medical devices, and innovative drug sectors [6][26]

2、公司未发现近期公共传媒报道了与公司相关且市场关注度较高的未公开重 大信息。 3、公司目前的经营情况及内外部经营环境未发生重大变化。 证券代码：002923 证券简称：润都股份 公告编号：2025-007 珠海润都制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况 珠海润都制药股份有限公司（以下简称"公司"）股票连续两个交易日（2025 年 04 月 08 日、04 月 09 日）收盘价格跌幅偏离值累计超过 20%，根据深圳证券交易 所的有关规定，属于股票交易异常波动的情况。 二、公司关注及核实情况的说明 针对公司股票异常波动，公司董事会进行了全面自查，并通过书面、电话问询 的方式，对公司控股股东、实际控制人就相关问题进行了核实，核实情况如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、公司于 2025 年 01 月 23 日披露《2024 年度业绩预告》。截至本公告披露日， 上述业绩预告不存在应修正的情况，公司 2024 年度具体财务数据请以公司 2024 年 年度报告为准。公司未 ...

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [35]. Core Insights - The pharmaceutical and biotechnology sector showed a 1.20% increase in performance from March 31 to April 3, ranking third among 31 industries and outperforming the CSI 300 index by 2.57 percentage points [11][16]. - Year-to-date, the sector has risen by 4.77%, ranking seventh among 31 industries and surpassing the CSI 300 index by 6.64 percentage points [16]. - The current PE valuation for the pharmaceutical and biotechnology sector stands at 27.2 times, which is at a historically low level, with a 130% premium compared to the CSI 300 index [20]. Market Performance - The top three sub-sectors in terms of growth last week were chemical pharmaceuticals (3.45%), traditional Chinese medicine II (1.53%), and pharmaceutical commerce (1.48%) [11]. - A total of 344 stocks (72.57% of the sector) experienced price increases last week, with the top five performers being Duorui Pharmaceutical (56.32%), Weisi Medical (31.80%), Hasanlian (31.15%), Rundu Co. (27.01%), and Shengnuo Biological (21.54%) [25][26]. Industry News - On April 4, the Ministry of Commerce announced investigations into the competitiveness of imported medical CT tubes and initiated anti-dumping investigations against imports from the United States and India [27][30]. - The investigations will assess the impact of these imports on the domestic industry and its competitiveness, covering the period from January 1, 2024, to December 31, 2024, for dumping and from January 1, 2022, to December 31, 2024, for industry damage [29][30]. Investment Recommendations - The report suggests focusing on sectors such as innovative drugs, medical services, and domestic market-oriented businesses, which are less affected by trade frictions [31]. - It highlights the potential for accelerated domestic substitution in high-end medical equipment and blood products due to ongoing tariff disputes [31]. - Recommended stocks include Beida Pharmaceutical, Laobaixing, Lingrui Pharmaceutical, Huaxia Eye Hospital, and Boya Biological, with additional stocks to watch being Tebao Biological, Kelun Pharmaceutical, International Medicine, Kaili Medical, and Nuotai Biological [32].

（原标题：润都股份龙虎榜：营业部净卖出742.89万元） 资金流向方面，今日该股主力资金净流入991.40万元，其中，特大单净流入7734.05万元，大单资金净流 出6742.65万元。近5日主力资金净流入7452.86万元。（数据宝） 润都股份4月3日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 中国银河证券股份有限公司厦门嘉禾路证券营业部 | 4248.35 | 730.46 | | 买二 | 中国银河证券股份有限公司成都益州大道证券营业部 | 2118.55 | 2.15 | | 买三 | 华鑫证券有限责任公司上海光复路证券营业部 | 1890.03 | 36.52 | | 买四 | 国盛证券有限责任公司深圳梅园路证券营业部 | 1571.51 | 5.71 | | 买五 | 中邮证券有限责任公司湖北分公司 | 1481.47 | 0.00 | | 卖一 | 国泰君安证券股份有限公司宜昌沿江大道证券营业部 | 1202.26 | 5080.62 | | 卖二 | 国泰君安证券股份有限公司深圳 ...

一、股票交易异常波动的情况 珠海润都制药股份有限公司（以下简称"公司"）股票连续两个交易日（2025 年 04 月 01 日、04 月 02 日）收盘价格涨幅偏离值累计超过 20%，根据深圳证券交易 所的有关规定，属于股票交易异常波动的情况。 二、公司关注及核实情况的说明 针对公司股票异常波动，公司董事会进行了全面自查，并通过现场、电话问询 的方式，对公司控股股东、实际控制人就相关问题进行了核实，核实情况如下： 1、公司前期披露的信息不存在需要更正、补充之处。 证券代码：002923 证券简称：润都股份 公告编号：2025-006 珠海润都制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 5、股票异常波动期间，不存在控股股东、实际控制人买卖公司股票的行为。 6、公司不存在违反公平信息披露规定的情形。 三、是否存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据《深圳证券交易所股票上市规则》 等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、协议 等；董事会也未获悉本公司有根据《深圳证券交 ...

Market Overview - The Shanghai Composite Index rose by 0.05% to 3350 points, with a total trading volume of 992.7 billion yuan, marking a drop below 1 trillion yuan for the first time in 50 trading days [1] - Over 2700 stocks in the market increased, with 48 stocks hitting the daily limit up and 19 stocks hitting the limit down [1] - Sectors such as outdoor camping, robotics, decoration, jewelry, beauty care, and wind power equipment saw significant gains [1] Stock Performance - Key stocks with notable increases include: - Kai Mei Te Qi (002549) up by 10.01% to 10.11 yuan, achieving a five-day limit up streak [2] - Run Du Jiao Ye (002923) up by 10.02% to 17.78 yuan, with four limit ups in seven days [2] - Xin Ya Da (600571) up by 10.01% to 18.24 yuan, marking three limit ups in six days [2] - Heng Run Co., Ltd. (603985) up by 10.01% to 17.04 yuan, with three consecutive limit ups [2] Trading Dynamics - The top three net buying stocks on the Dragon and Tiger list were: - Dong Tu Ke Ji (300353) with a net buy of 215 million yuan [3] - Dian Tou Chan Rong (000958) with a net buy of 195 million yuan [3] - Qin Chuan Ji Chuang (000837) with a net buy of 180 million yuan [3] - Conversely, the top three net selling stocks were: - Hang Fa Dong Li (600893) with a net sell of 1.447 billion yuan [6] - Xue Ren Gong Si (002639) with a net sell of 126 million yuan [6] - Hong Bao Li (002165) with a net sell of 124 million yuan [6] Sector Highlights - The electric investment and financing sector is gaining attention due to its proposed acquisition of 100% equity in Electric Investment Nuclear Power, enhancing its position in the nuclear power sector [9][13] - Run Du Jiao Ye is focusing on new tobacco and synthetic biology, with a significant increase in trading volume and price [14][17] Institutional Activity - Institutions showed strong interest in Dong Tu Ke Ji, with a net buy of 794 million yuan [7] - Conversely, institutions sold off Hang Fa Dong Li significantly, with a net sell of 1.478 billion yuan [8] Summary of Key Stocks - Kai Mei Te Qi (002549) and Run Du Jiao Ye (002923) are leading in terms of price increases and trading activity, indicating strong market interest [2][14] - The performance of Dong Tu Ke Ji and Hang Fa Dong Li reflects contrasting investor sentiment, with one attracting significant buying and the other facing heavy selling pressure [7][8]

| 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 国泰君安证券股份有限公司深圳益田路证券营业部 | 4500.64 | 0.00 | | 买二 | 国泰君安证券股份有限公司宜昌沿江大道证券营业部 | 1407.81 | 556.49 | | 买三 | 中泰证券股份有限公司深圳分公司 | 1161.39 | 0.17 | | 买四 | 华鑫证券有限责任公司上海分公司 | 1120.12 | 8.15 | | 买五 | 长江证券股份有限公司深圳泰然五路证券营业部 | 1080.14 | 1.89 | | 卖一 | 开源证券股份有限公司西安西大街证券营业部 | 0.00 | 4210.80 | | 卖二 | 机构专用 | 0.00 | 2294.84 | | 卖三 | 机构专用 | 651.59 | 1558.64 | | 卖四 | 机构专用 | 0.00 | 1508.98 | | 卖五 | 中信建投证券股份有限公司福州东街证券营业部 | 28.54 | 1370.75 | （文章来源：证券时报网） 具体来看，今日上榜 ...

民生证券认为，中国本土医药创新逐渐进入收获期，国际化进程持续加速，继续重点看好医药创新主 线，同时医药板块基本面持续向上复苏，同时看好医药消费主线。 国金证券研报称，一方面，市场对医药板块政策预期转向乐观，创新药和部分仿制药板块表现强势；另 一方面，随着年报逐步披露和一季报预期逐步形成，市场开始交易医药部分左侧赛道和左侧板块复苏、 困境反转预期。医药板块在一季度以后的景气度复苏和估值修复是极大概率事件，建议积极把握4月一 季报布局窗口。 3月25日，广州试点创新药械"医保+商保"同步结算，将创新药械纳入商业健康保险保障，进一步完善了 创新药械的多元化支付探索。 日前，上海市卫健委表示，今年还将完善多元支付机制，聚焦"进目录"和"进医院"，推动创新药械挂 网、纳保、入院、支付有序高效衔接，积极推荐该市创新药纳入国家医保丙类药品目录。 光大证券研报指出，全国各地均在积极推进创新药械的多渠道支付覆盖和支持，为患者带来福音，更对 创新药市场格局产生深远影响，有望重塑行业发展轨迹。从商业健康保险角度来看，惠民保、百万医疗 险、中高端医疗险等产品不断丰富。免息金融分期支付方案也在探索中，多元化支付体系逐步成型。这 有利于 ...